Pharmacogenetic landscape of epidermal growth factor receptor mutations in Kurdish non-small cell lung cancer patients: implications for precision oncology.

Badraldin K Hamad, Sami Saleem Omar, Iman H F Alnaqshabandy, Rawaz D Tawfeeq, Sarween A Abdullah, Aveen R Jalal

Abstract read

In one paragraph

Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Badraldin K HamadPharmacology Department, College of Pharmacy, Hawler Medical University, Erbil 44001, Iraq.

Sami Saleem OmarMedical Oncologist, Rizgary Oncology Center - Rizgary Teaching Hospital, Erbil 44001, Iraq.

Iman H F AlnaqshabandyDepartment of Scientific Research Center, College of Science, University of Duhok, Duhok, Kurdistan Region 42001, Iraq.

Rawaz D TawfeeqClinical Analysis Department, College of Pharmacy, Hawler Medical University, Erbil 44001, Iraq.

Sarween A AbdullahPharmacology Department, College of Pharmacy, Knowledge University, Erbil 44001, Iraq.

Aveen R JalalSchool of Sport, Exercise and Health Sciences. Loughborough University, 42001 Loughborough, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work presents the first thorough examination of epidermal growth factor receptor (EGFR) mutation prevalence in Kurdish patients with non-small cell lung cancer (NSCLC), identifying unique molecular and epidemiological traits. We found an overall EGFR mutation rate of 18.2% among 149 metastatic non-squamous NSCLC cases, which is comparable to Middle Eastern cohorts but much lower than rates reported in East Asian populations (47.2%-64.2%). Significant gender differences were found, with females (55.6%) having EGFR mutations at a significantly higher rate than males (44.4%, *

Indexed as

EGFR mutationsKurdish populationnon-small cell lung cancerprecision medicinetyrosine kinase inhibitors

Identifiers

PMID42131887

DOI10.3332/ecancer.2026.2087

PMCPMC13161589

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.